6-Dehydroprogesterone
6-Dehydroprogesterone structure
|
Common Name | 6-Dehydroprogesterone | ||
|---|---|---|---|---|
| CAS Number | 1162-56-7 | Molecular Weight | 312.446 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 462.8±45.0 °C at 760 mmHg | |
| Molecular Formula | C21H28O2 | Melting Point | 146 °C | |
| MSDS | N/A | Flash Point | 172.2±25.7 °C | |
|
Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Gynecol. Endocrinol. 29(2) , 165-8, (2013) It is established that hormone therapy (HT) is related with significant increased prothrombotic risk factor. The aim of our study was to assess the effects of oral hormone therapy (o-HT) and transdermal hormone therapy (t-HT) on hemostasis parameters: fibrino... |
|
|
Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety.
Maturitas 76(1) , 10-21, (2013) HRT is known to be effective for the relief of menopausal symptoms and prevention of osteoporosis. HRT should be tailored to the woman, enhancing the beneficial effects of the treatment while minimizing the risks. It is difficult to evaluate data on particula... |
|
|
Hormone replacement therapy regimens in chemotherapy-induced premature ovarian failure and the subsequent correction of hormone levels.
Neuro Endocrinol. Lett. 33(7) , 697-702, (2012) Premature ovarian failure (POF) is a consequence of gonadotoxic chemoradiotherapy given in antyneoplasia treatment. In young women it will correlate with menopausal symptoms which tend to appear due to depleted ovarian follicle reserve.It was a case series st... |
|
|
Beneficial influence of postmenopausal estrogen therapy on serum adhesion molecules is independent of the route and dose of administration.
Neuro Endocrinol. Lett. 32(3) , 340-4, (2011) In current literature, the immune-inflammatory theory of atherosclerosis is widely discussed. The role of how adhesion molecules contribute to the development of atheromatic plaques is especially underlined.120 females in menopausal age were included in the s... |
|
|
Successful use of dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a case report.
Jpn. J. Clin. Oncol. 43(11) , 1145-9, (2013) Endometrial stromal sarcoma is known to be a hormone-dependent tumor. Efficacy of hormonal therapy including high-dose progestins, aromatase inhibitors or gonadotropin-releasing hormone analogs has been reported. We report a case of recurrent endometrial stro... |
|
|
Progestagens and anti-progestagens for pain associated with endometriosis.
Cochrane Database Syst. Rev. 3 , CD002122, (2012) Endometriosis is a chronic inflammatory condition defined by the presence of glands and stroma outside the uterine cavity. It occurs in 7% to 10% of all women of reproductive age and may present as pain or infertility. The pelvic pain may be in the form of dy... |
|
|
Dydrogesterone does not reverse the cardiovascular benefits of percutaneous estradiol.
Climacteric 16(1) , 54-61, (2013) To evaluate the influence of dydrogesterone on estimated cardiovascular risk of users of hormone replacement therapy (HRT) (with percutaneous 17β-estradiol in monotherapy and in combination with dydrogesterone) and HRT non-users through the Framingham score t... |
|
|
Biotechnological production of 20-alpha-dihydrodydrogesterone at pilot scale.
Appl. Biochem. Biotechnol. 165(1) , 190-203, (2011) The human sex hormone progesterone plays an essential and complex role in a number of physiological processes. Progesterone deficiency is associated with menstrual disorders and infertility as well as premature birth and abortion. For progesterone replacement... |
|
|
Selectivity and potency of the retroprogesterone dydrogesterone in vitro.
Steroids 76(6) , 607-15, (2011) Dydrogesterone is widely used for menstrual disorders, endometriosis, threatened and habitual abortion and postmenopausal hormone replacement therapy. Although progestins have a promiscuous nature, dydrogesterone does not have clinically relevant androgenic, ... |
|
|
Changes in hemostatic parameters after oral and transdermal hormone therapy in postmenopausal women.
Gynecol. Endocrinol. 27(9) , 692-5, (2011) Hormone therapy (HT) can be prothrombotic risk factor. We compared the effects of oral HT (o-HT) and transdermal HT (t-HT) on the kinetic of clot formation and fibrinolysis in postmenopausal women after 6 months HT using a multiparameter test. We observed tha... |